Enbrel® (etanercept) was acclaimed “Brand of the Year” by Med Ad News, a leading healthcare industry magazine, marking the first time that a biologic therapy has received the honor. The distinction appeared in the June issue of Med Ad News.
The publication awards the annual accolade to a Top 100 best-selling prescription human therapeutic that has achieved double-digit growth based on worldwide sales. More than 381,000 patients worldwide have used ENBREL in moderate-to-severe RA, moderate-to-severe plaque psoriasis, ankylosing spondylitis, moderate-to-severe polyarticular-course juvenile rheumatoid arthritis (JRA) or psoriatic arthritis.
To learn more about ENBREL, visit http://www.enbrel.com/.
